EUVIMEDOpdag EUVIMED
Crossref

Intratumoral Holmium-166 Microsphere Injection in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Center, Single-Arm, Open-Label Feasibility and Safety Study

C Ysbrand Willink, Sjoerd F M Jenniskens, Martijn W J Stommel, Marcel J R Janssen, John J Hermans, Harm Westdorp, Cornelis J H M van Laarhoven, Jurgen J Fütterer, J Frank W Nijsen

Digestive Surgery · 2025

DOI: 10.1159/000545246 ↗

At a glance

Journal article in Digestive Surgery, 2025. Written by C Ysbrand Willink and 8 co-authors. Institution: Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands. Major MEDLINE topics: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Holmium, Radioisotopes. Cited 2 times so far (Crossref); 26 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and lacks local treatment options. This study aimed to assess the feasibility and safety of the first-in-human intraoperative ultrasound-guided intratumoral injection of radioactive holmium-166 microsphere in patients with PDAC.

Methods

Patients with proven PDAC eligible for open surgical resection were included. If resection was abandoned during exploration, study intervention was performed. Feasibility was defined by injection success and on-/off-target radiation. Safety was based on adverse event (AE) monitoring for 12 weeks categorized by severity grade and study attribution.

Results

Three of the thirteen included patients received study intervention. Injection was successful in all 3 patients. Mean tumor doses of 5.0, 17.0, and 39.0 Gy and maximum tumor doses of 25.0, 41.0 and 256.0 Gy were achieved. Off-target radiation was found once in the lungs and once in the colon with a mean dose

Subjects

MeSH terms (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHolmiumRadioisotopesHumansFeasibility StudiesMaleFemaleMicrospheresAgedMiddle AgedInjections, IntralesionalUltrasonography, InterventionalAged, 80 and over

Author keywords

BrachytherapyHolmium microspheresIntratumoral injectionPancreatic cancerPancreatic ductal adenocarcinoma

Substances

HolmiumHolmium-166Radioisotopes

Authors and institutions

  • Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.

Cite

APA

Willink, C. Y., Jenniskens, S. F. M., Stommel, M. W. J., Janssen, M. J. R., Hermans, J. J., Westdorp, H., van Laarhoven, C. J. H. M., Fütterer, J. J., & Nijsen, J. F. W. (2025). Intratumoral Holmium-166 Microsphere Injection in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Center, Single-Arm, Open-Label Feasibility and Safety Study. Digestive Surgery. https://doi.org/10.1159/000545246

Vancouver

Willink CY, Jenniskens SFM, Stommel MWJ, Janssen MJR, Hermans JJ, Westdorp H, et al. Intratumoral Holmium-166 Microsphere Injection in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Center, Single-Arm, Open-Label Feasibility and Safety Study. Digestive Surgery. 2025. doi:10.1159/000545246

BibTeX
@article{Willink2025,
  author = {Willink, C Ysbrand and Jenniskens, Sjoerd F M and Stommel, Martijn W J and Janssen, Marcel J R and Hermans, John J and Westdorp, Harm and van Laarhoven, Cornelis J H M and Fütterer, Jurgen J and Nijsen, J Frank W},
  title = {Intratumoral Holmium-166 Microsphere Injection in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Center, Single-Arm, Open-Label Feasibility and Safety Study},
  journal = {Digestive Surgery},
  year = {2025},
  doi = {10.1159/000545246}
}
Start for free →